A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
This Study is
No Longer Enrolling
Details
Age
Child to Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Study ID
Protocol Number: 21-3431
More information available at ClinicalTrials.gov: NCT04985604
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers